Novartis AG’s lung cancer treatment ceritinib has been in the spotlight in India following a hotly contested patent infringement case against local firm Natco Pharma Ltd. Now, an interesting pricing scenario playing out for the product has highlighted the discounting approach and business strategies of e-pharmacies in the country.
Launched in May 2016, Novartis’s ceritinib - sold as Spexib in India (Zykadia internationally) - was recently listed at INR2,416 ($35.03) for a strip of 10 capsules, a whopping 69%...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?